Esma K. Shoua

Esma K. Shoua

Auto-generated profile, based on publicly available information

Esma K. Shoua

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2021 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
TZT. N. Zabotina
T. N. Zabotina
ACA. I. Chertkova
A. I. Chertkova
ABA. A. Borunova
A. A. Borunova
EZE. N. Zakharova
E. N. Zakharova
ESE. K. Shoua
E. K. Shoua
AKA. G. Kadagidze
A. G. Kadagidze
Introduction. Breast cancer (BC) is an immunogenic tumor. Immune cells infiltration of tumor tissue can affect the clinical course of the disease. The immunogenicity of breast cancer varies depending on the molecular subtype.The aim of this work was to study the main indicators of systemic and local immunity before patient’s treatment and to determine their relationship with the immediate neoadjuvant chemotherapy results.Materials and methods. Patients with stage II–III BC received standard neoadjuvant chemotherapy in accordance with the molecular subtypes. The percentage of the main effector and regulatory lymphocytes populations of systemic and local immunity was determined by flow cytometry.Results. A decrease in the level of effector CD8 and CD4 lymphocyte populations and an increase in the level suppressor populations in tumor tissue in comparison with peripheral blood indicate an immunosuppressive state of local immunity in BC patients. In tumor tissue, a high level of CD8+ PD-1+ and CD4+ PD-1+ cells were associated with a high level of regulatory CD4+ CD25highCD127–/low and CD8+ CD11b– CD28– lymphocytes. Differences were found in the significance of individual lymphocyte populations for the immediate results of treatment between patients with different subtypes of breast cancer.Conclusion. Determination of lymphocyte subpopulations correlating with the level of PD-1 cells, and the results of treatment in patients with different molecular BC subtypes, will help a clearer understanding of the antitumor immune response in this pathology, and will also serve as a basis for identifying immune biomarkers that can be used as additional predictive factors in various treatment options for BC patients.

1 January 2021 in Immunologiya
Verified
Journal Article
Closed access
ZKZ.G. Kadagidze
Z.G. Kadagidze
NFN.N. Blokhin National Medical Research Center of Oncology» of Ministry of Health of the Russian Federation
N.N. Blokhin National Medical Research Center of Oncology» of Ministry of Health of the Russian Federation
ACA.I. Chertkova
A.I. Chertkova
TZT.N. Zabotina
T.N. Zabotina
OGO.O. Gordeeva
O.O. Gordeeva
DTDmitrii V. Tabakov
Dmitrii V. Tabakov

8 December 2020 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
ABA. A. Borunova
A. A. Borunova
TZT. N. Zabotina
T. N. Zabotina
ESE. K. Shoua
E. K. Shoua
GCG. Z. Chkadua
G. Z. Chkadua
ACA. I. Chertkova
A. I. Chertkova
ZKZ. G. Kadagidze
Z. G. Kadagidze
Introduction. Long-term monitoring of immune system parameters in cancer patient in FSBI “N.N. Blokhin Medical Research Center of Oncology” of the Ministry of Health of Russia, as well as the absence of an immunological research algorithm and a spectrum of significant markers, served as the basis for this study.Purpose. To present reference values and determine the normal range for subpopulations of systemic immunity lymphocytes.Materials and methods. The phenotype of peripheral blood lymphocytes was studied in 186 healthy donors (86 men and 100 women), mean age 41,9 ± 12,5 years. To assess the multivariate phenotype by flow cytometry, monoclonal antibodies to CD45, CD3, CD4, CD8, CD16, CD56, CD19, CD25, CD28, CD11b, CD127, HLA-Dr, TCR-γ / δ, Perforin and Granzime B labeled various fluorochromes.Results. A panel of markers of immunocompetent cells of systemic immunity was developed as a basis for assessing the state of the immune system of cancer patients. Reference values and normal boundaries are given for characterizing the linearity of cells with detailing of the phenotypic and functional heterogeneity of the population of CD8+-lymphocytes, activation markers and the pool of naive cells; characteristics of various types of regulatory cells, functional activity of cells of the effector link of immunity. A comparative analysis of immunoregulatory indices was carried out and the vulnerability of the formula CD3+CD4+/CD3+CD8+ to the CD4+/CD8+ index was proved.Conclusion. The spectrum of the proposed indicators is the product of many years of research carried out in the laboratory of clinical immunology of the Federal State Budgetary Institution “N.N. Blokhin National Medical Research Center of Oncology” оf the Ministry of Health of the Russian Federation, in order to search for significant criteria for assessing the state of the immune system in cancer.

1 January 2020 in Immunologiya
Verified
Journal Article
Closed access
NFN.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation
N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation
TZT.N. Zabotina
T.N. Zabotina
ACA.I. Chertkova
A.I. Chertkova
ZKZ.G. Kadagidze
Z.G. Kadagidze
ABA.A. Borunova
A.A. Borunova
AMA.A. Meshcheryakov
A.A. Meshcheryakov

10 December 2023 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
TZTatiana N. Zabotina
Tatiana N. Zabotina
ACAntonina I. Chertkova
Antonina I. Chertkova
ABAnna A. Borunova
Anna A. Borunova
NKNikolay E. Kushlinskii
Nikolay E. Kushlinskii
EGElena S. Gershtein
Elena S. Gershtein
ХВХорошилов Максим Викторович
Хорошилов Максим Викторович
Background. The PD-1/PD-L1 pathway plays an important role in tumor evasion from immunological surveillance. In addition to the membrane forms of PD-1 and PD-L1, there are soluble variants: sPD-1 and sPD-L1. Both membrane and soluble forms have immunoregulatory properties and can affect the function and number of different immune cell populations. Aim. To study the relationship between the initial level of CD8⁺PD-1⁺ and CD4+PD-1⁺ lymphocytes and soluble forms of sPD-1 and sPD-L1 with the percentage of the main effector and regulatory populations of peripheral blood (PB) lymphocytes and tumor-infiltrating lymphocytes. Materials and methods. The study included melanoma, breast cancer and the oral mucosa cancer patients. The percentage of cell populations of PB lymphocytes and tumor-infiltrating lymphocytes was determined by flow cytometry before treatment. The concentrations of sPD-1 and sPD-L1 proteins were studied in blood serum using enzyme immunoassay. Results. The relationship of the level of CD8⁺PD-1⁺ cells with certain populations of CD8-lymphocytes in PB and tumor tissue was found. In the PB of melanoma patients with CD8⁺CD11b⁺CD28⁺ and CD8⁺CD11b⁻CD28⁻ T cells, in breast cancer patients with a population of CD8⁺CD11b⁺CD28⁺ lymphocytes. In the tumor tissue of all patients there was a positive correlation with a population of regulatory CD8⁺CD11b⁻CD28⁻ T cells. The immunoregulatory properties of sPD-1 and sPD-L1 were confirmed. Both sPD-1 and sPD-L1 levels were positively correlated with the number of suppressor CD8⁺CD11b⁻CD28⁻ T cells and negatively with the level of CD8 lymphocytes, CD8⁺CD11b⁺CD28⁺ cytotoxic/memory T cells, B cells and activated CD25 lymphocytes. Conclusion. The results of the study can make a certain contribution to the study of the prognostic significance of membrane and soluble forms of PD-1 and PD-L1, taking into account the peculiarities of their relationship with suppressor and effector populations of lymphocytes of systemic and local immunity.

1 January 2023 in Immunologiya
Verified
Journal Article
Open access
ABA.A. Borunova
A.A. Borunova
ESE.K. Shoua
E.K. Shoua
EZE.N. Zakharova
E.N. Zakharova
ACA.I. Chertkova
A.I. Chertkova
ZKZ.G. Kadagidze
Z.G. Kadagidze
TZT.N. Zabotina
T.N. Zabotina
Особенности клеточного иммунитета медицинских работников в первую волну пандемии SARS-CoV-2-инфекции